Research programme: dispersin B-based anti-infectives - Kane Biotech

Drug Profile

Research programme: dispersin B-based anti-infectives - Kane Biotech

Alternative Names: Biofilm inhibitors - Kane Therapeutics; Dispersin B-based antibiofilm therapeutics - Kane Biotech; Dispersin B-based wound care therapeutics - Kane Biotech; Dispersin B/Gentamicin; DispersinB Topical wound gel; DispersinB-Gentamicin wound gel spray; Gentamicin/dispersin B

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator University of Medicine & Dentistry of New Jersey
  • Developer Kane Biotech
  • Class Aminoglycosides; Proteins; Small molecules
  • Mechanism of Action Glycoside hydrolase stimulants; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections(Prevention) in Canada (Topical, Gel)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Canada (Topical, Gel)
  • 04 Aug 2015 Kane Biotech extends CRADA with the US Army Institute of Surgical Research for the development of dispersin B-based products for Bacterial infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top